| IBS pain and discomfort — 35624 | Pain and discomfort scores on a 0–5 scale fell by 0.89 points with strain 35624 versus 0.58 points with placebo. The additional reduction was 0.31 points (p = 0.023). | 2/4 LowThe trial included only women with IBS and lasted 4 weeks. The 100 million CFU dose showed an advantage. The highest-dose capsule had formulation problems, and the results do not support a simple “more is better” rule. | 1publicationEfficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome ↗ | 362 women aged 18–65 with irritable bowel syndrome and varying bowel habits | - Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome ↗
|
|---|
| Symptoms of IBS with diarrhea — live ES1 | The total IBS-SSS symptom score on a 0–500 scale fell by 173.70 points with live ES1 versus 60.44 points with placebo (p < 0.0001). | 2/4 LowOne trial of a specific strain in adults with IBS with diarrhea. The total score measures symptom severity. It does not show what proportion of participants recovered from IBS. | 1publicationA randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome ↗ | 200 adults aged 18–65 with irritable bowel syndrome with diarrhea, of whom 197 had data after starting the regimen | - A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome ↗
|
|---|
| Symptoms of IBS with diarrhea — inactivated HT-ES1 | The total IBS-SSS symptom score on a 0–500 scale fell by 177.60 points with inactivated HT-ES1 versus 60.44 points with placebo (p < 0.0001). | 2/4 LowThe result comes from one trial of the heat-treated preparation in adults with IBS with diarrhea. The dose and formulation differed from those in the allergic rhinitis study. The strain name alone does not make these products interchangeable. | 1publicationA randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome ↗ | 200 adults aged 18–65 with irritable bowel syndrome with diarrhea, of whom 197 had data after starting the regimen | - A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome ↗
|
|---|
| Overall constipation score in older adults — BB536 | Over 4 weeks, the change in the total CSS constipation score did not differ significantly from placebo (p = 0.074). | 2/4 LowThe trial included 80 older adults, of whom 79 were analyzed. It assessed the overall constipation score. The separate bowel movement frequency subscale changed differently, but its scores cannot be converted into a number of additional bowel movements. | 1publicationUsefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial ↗ | 80 people aged 65 and older with chronic constipation, including IBS with constipation. The analysis included 79 people, and the mean age was about 78 years. | - Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial ↗
|
|---|
| Perceived stress — NCC3001 | The Perceived Stress Scale (PSS) score on a 0–56 scale was 3.28 points lower than with placebo. The 95% confidence interval indicated a reduction of 0.62–5.93 points (p = 0.017). | 2/4 LowA small exploratory trial in which 49 people were assigned to groups and 45 were included in the main analysis. This was a self-reported measure of stress in generally healthy adults. The result does not establish that all anxiety symptoms improved. | 1publicationBifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗ | 49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis | - Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗
|
|---|
| Anxiety — NCC3001 | The difference in HADS-A anxiety scores was −0.65 points (95% confidence interval −2.05 to 0.76 points, p = 0.358). | 2/4 LowAnxiety was assessed as a separate outcome in a small trial of people with elevated stress. The interval includes both a decrease and a small increase in the score, so it does not establish that the two regimens had exactly the same effect. | 1publicationBifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗ | 49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis | - Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗
|
|---|
| Overall sleep score — 1714 | After 8 weeks, the total PSQI sleep quality score on a 0–21 scale was 4.0 with strain 1714 versus 4.3 with placebo (p = 0.64). A lower score indicates fewer sleep problems. | 2/4 LowParticipants reported sleep problems and had no diagnosis of insomnia. Some participants’ sleep complaints had already eased between screening and the start of the regimen. The result applies to this group over 8 weeks. | 1publicationBifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗ | 89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia. | - Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗
|
|---|
| Overall sleep score — NCC3001 | The difference in total PSQI scores was −0.38 points (95% confidence interval −1.13 to 0.37 points, p = 0.308). | 2/4 LowSleep was assessed as an additional outcome in a small trial of people with stress. Many did not have substantial sleep problems at baseline. The conclusion applies to the total PSQI score. A separate rating of subjective sleep quality cannot substitute for this measure. | 1publicationBifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗ | 49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis | - Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗
|
|---|
| Sleep measured by a wrist-worn device — 1714 | In weeks 5–8, the percentage of time spent asleep was 92% with strain 1714 versus 91% with placebo. The device recorded an average of 15 versus 16 awakenings. Differences in these measures, in time to fall asleep, and in time spent awake after falling asleep were not statistically significant. | 2/4 LowThe wrist-worn device estimated sleep from movement, separately from the questionnaire responses. The p-values for the four measures were 0.95, 0.29, 0.69, and 0.34. The trial did not study treatment for diagnosed insomnia. | 1publicationBifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗ | 89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia. | - Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗
|
|---|
| Individual sleep complaints at 4 weeks — 1714 | At 4 weeks, sleep quality scores were 1.0 versus 1.2 points with placebo, and daytime difficulty scores were 0.5 versus 0.7 points with placebo, on 0–3 scales. These differences were no longer statistically significant after adjustment for multiple comparisons. | 1/4 Very lowThese are individual components of the questionnaire, separate from its overall score. The researchers tested many measures at the same time, increasing the likelihood of a chance finding. At eight weeks, there was no sustained advantage on these questionnaire components. | 1publicationBifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗ | 89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia. | - Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗
|
|---|
| Visual memory and learning — 1714 | At the end of the supplementation period, the mean number of errors on the PAL task was 2.30 with 1714 and 2.42 with placebo. No statistically significant difference was found. | 1/4 Very lowOnly 20 male students completed both periods, out of 30 participants assigned to groups. Repeated testing itself improves performance. A change within a single period does not establish an effect of the supplement. | 1publicationImprovements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗ | 30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years. | - Improvements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗
|
|---|
| Sustained attention — 1714 | At the end of the supplementation period, the mean number of correctly detected signals on the RVP test was 23.80 with 1714 and 23.30 with placebo. No statistically significant difference was found. | 1/4 Very lowThis was a very small trial of male students during exams. Twenty participants completed both periods. Performance also improved with repeated testing without the supplement. The result cannot be generalized to all types of attention. | 1publicationImprovements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗ | 30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years. | - Improvements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗
|
|---|
| Emotion recognition — 1714 | The proportion of correct responses on the ERT emotion recognition test was 78.19% with 1714 and 77.56% with placebo. No statistically significant difference was found. | 1/4 Very lowThe study was small and had substantial dropout. Twenty male students completed both periods. The study measured performance on a specific computer task. The ability to understand other people more broadly was outside its scope. | 1publicationImprovements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗ | 30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years. | - Improvements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗
|
|---|
| Depressive symptoms on the Beck Depression Inventory — 1714 | At 8 weeks, the between-group difference in BDI-II score change was −1.43 points (95% confidence interval −3.30 to 0.44 points, p = 0.132). | 2/4 LowThis was the primary outcome in a trial of people with mild or moderate depressive symptoms. The interval includes the possibility of no difference. The finding applies to the Beck Depression Inventory. It does not combine the mood measures that were assessed separately. | 1publicationEffects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial ↗ | 168 adults aged 18–70 with mild or moderate depressive symptoms. Eligibility required meeting criteria for a depressive disorder. | - Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial ↗
- The Effects of Bifidobacterium Longum 1714 in a Population With Low Mood — NCT04925440 ↗
|
|---|
| Allergic rhinitis during usual medication use — HT-ES1 | At 8 weeks, the total CSMS on a 0–6 scale was 0.60 points lower than with placebo (95% confidence interval for the reduction 0.09–1.12 points, p = 0.022). The score accounts for both symptoms and medication use. | 2/4 LowThis was a small trial. The primary analysis included 25 people in the HT-ES1 group and 22 in the placebo group. Four weeks after stopping the supplement, the difference was no longer statistically significant. The result was observed when HT-ES1 was used alongside usual medications. | 1publicationEffects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial ↗ | 72 adults aged 18–60 with moderate or severe allergic rhinitis. Of these, 64 began taking their assigned capsules and were included in the primary analysis. | - Effects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial ↗
- Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis ↗
|
|---|
| Allergic rhinitis during usual medication use — live ES1 | Live ES1 showed no statistically significant advantage over placebo on the combined symptom and medication use score (CSMS) at either the 8-week assessment or the assessment 4 weeks after supplementation ended. | 2/4 LowSeven people dropped out of the live ES1 group before taking any capsules. The primary analysis included 17 people in the ES1 group and 22 in the placebo group. The small group limits the precision of the estimate. The result for inactivated HT-ES1 cannot be attributed to live ES1. | 1publicationEffects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial ↗ | 72 adults aged 18–60 with moderate or severe allergic rhinitis. Of these, 64 began taking their assigned capsules and were included in the primary analysis. | - Effects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial ↗
- Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis ↗
|
|---|
| Body weight — BL21 | Over 8 weeks, body weight decreased by 1.22 kg with BL21 and 0.98 kg with placebo. The difference in weight loss was 0.24 kg (p = 0.57), which was not statistically significant. | 2/4 LowThe analysis included 66 of the 72 participants with overweight or obesity. This short trial of a specific strain did not establish a weight-loss advantage. | 1publicationMulti-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study ↗ | 72 adults aged 18–65 with overweight or obesity, of whom 66 were included in the analysis | - Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study ↗
|
|---|
| Body mass index — APC1472 | The between-group difference in BMI change was 0.03 kg/m², with a published 95% confidence interval of −0.4 to 0.3 kg/m². There was no statistically significant difference. | 2/4 LowIn the human trial, participants took this strain for 12 weeks. Their baseline BMI was 28–34.9 kg/m². The same publication also reports animal experiments. The weight findings from those experiments cannot be generalized to the human trial participants. | 1publicationBifidobacterium longum counters the effects of obesity: Partial successful translation from rodent to human ↗ | 124 adults aged 18–65 with a BMI of 28–34.9 kg/m². BMI results were reported for 122 participants. | - Bifidobacterium longum counters the effects of obesity: Partial successful translation from rodent to human ↗
|
|---|